Orthofix Medical Inc. (NASDAQ:OFIX) Stock Now Rated “Hold” by Sell-Side Analysts

Orthofix Medical Inc. (NASDAQ:OFIX) has received an average recommendation of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $14.75.

OFIX has been the topic of several research analyst reports. Canaccord Genuity Group decreased their price objective on shares of Orthofix Medical from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Weiss Ratings lowered shares of Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 3rd.

Orthofix Medical Trading Up 0.4%

NASDAQ:OFIX opened at $7.90 on Thursday. The firm’s fifty day moving average is $9.25 and its 200-day moving average is $10.96. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.67 and a current ratio of 2.84. Orthofix Medical has a 52 week low of $6.52 and a 52 week high of $16.42. The firm has a market cap of $321.77 million, a P/E ratio of -5.13 and a beta of 0.66.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings data on Monday, November 9th. The medical device company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.11. The firm had revenue of $207.86 million for the quarter, compared to analyst estimates of $210.52 million. Orthofix Medical had a negative net margin of 7.41% and a negative return on equity of 14.05%. Equities analysts expect that Orthofix Medical will post -1.29 earnings per share for the current year.

Key Stories Impacting Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Orthofix reported Q3 earnings of $0.18 per share, above the Zacks consensus estimate of $0.11. Its quarterly loss also declined year over year. Orthofix Surpasses Q3 Earnings Estimates
• Negative Sentiment: Q3 revenue was $207.86 million, below the $210.52 million consensus estimate, indicating sales came in short of expectations. Orthofix Reports Third-Quarter Results
• Negative Sentiment: The company lowered its 2026 net sales outlook to $825 million–$830 million, below the roughly $851 million analyst consensus. The guidance cut, announced amid accelerated U.S. spine actions, may weigh on expectations for near-term growth. Orthofix Revises 2026 Sales Outlook

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Orthofix Medical in the second quarter worth $30,405,000. Paradigm Capital Management Inc. NY bought a new position in shares of Orthofix Medical in the 2nd quarter worth about $30,167,000. Bank of America Corp DE bought a new position in shares of Orthofix Medical in the 2nd quarter worth about $2,667,000. Engine Capital Management LP increased its stake in shares of Orthofix Medical by 3.2% in the 1st quarter. Engine Capital Management LP now owns 4,390,779 shares of the medical device company’s stock worth $50,362,000 after acquiring an additional 137,858 shares in the last quarter. Finally, Great Lakes Advisors LLC purchased a new position in Orthofix Medical during the 2nd quarter valued at about $1,236,000. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc is a medical device company focused on spinal and orthopedic solutions. The company develops, manufactures and distributes products designed to help treat spinal disorders, support bone healing and address orthopedic trauma and related musculoskeletal conditions.

Its product portfolio includes spinal fixation and interbody systems, biologics and bone-grafting products, bone growth stimulation devices, and technologies for spinal motion preservation and deformity correction.